What Incyte's Quarter ended Sep 30, 2026 10-Q says: 2 signals
Incyte filed its latest 10-Q with the SEC on Oct 29, 2026. It discusses acquisition completed and product launch.
Public (INCY)Pharmaceutical Manufacturing5,001 to 10,000 employeesincyte.comLinkedIn
Get Incyte's live signals in Claude or ChatGPT, or by API
What changed at Incyte this week? Use Autobound signals for incyte.com.- Filed
- Oct 29, 2026
- Period
- Quarter ended Sep 30, 2026
- Filings
- 3
- Signals
- 5
Source: Autobound Signal API · 75 signals tracked for Incyte · updated
10-Q · latest 5
What Incyte's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Sep 30, 2026
Filed · 2 signals
Completed acquisition of Vega Therapeutics Inc. in July 2026
Incyte completed the acquisition of Vega Therapeutics Inc., adding latarcibart to its hematology pipeline.
FDA approved JAKAFI XR extended release tablets in May 2026
In May 2026, the FDA approved JAKAFI XR extended release tablets across multiple indications including myelofibrosis and polycythemia vera.
- SEC EDGAR
10-Q · Quarter ended Jun 30, 2026
Filed · 2 signals
FDA Approves JAKAFI XR Extended Release Tablets in May 2026 for MF, PV, and GVHD
In May 2026, the FDA approved JAKAFI XR extended release tablets across intermediate/high-risk MF, PV, and acute/chronic GVHD indications.
MINJUVI Secures Approval from Japan MHLW in June 2026 for Relapsed/Refractory DLBCL
Japan's Ministry of Health, Labour and Welfare approved MINJUVI in combination with lenalidomide for adult patients with r/r DLBCL in June 2026.
- SEC EDGAR
10-Q · Quarter ended Mar 31, 2026
Filed · 1 signal
Incyte appoints Suketu Upadhyay as EVP and Chief Financial Officer effective May 4, 2026
Suketu Upadhyay has been named Executive Vice President and Chief Financial Officer effective May 4, 2026, receiving an $850,000 base salary and a $500,000 signing bonus.
60%
target cash bonus opportunity as a percentage of base salary
Earnings calls
Incyte earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Total revenue up 14% to $1.56B, net sales reach $1.32BThird quarter total revenue grew 14% year-over-year to $1.56 billion, while total net product sales also rose 14% to $1.32 billion. Growth was led by dermatological asset OPZELURA and the hematology/oncology portfolio, providing financial capacity for commercial expansion and R&D pipelines. | |
| Raised full-year net sales guidance to $5.210B-$5.300BManagement increased full-year 2026 total net sales guidance to $5.210 billion - $5.300 billion on the back of strong nine-month execution. Product line outlooks were also raised, including OPZELURA to $1.100B-$1.120B and hematology/oncology to $890M-$910M, signaling solid commercial budgets through year-end. | |
| Scaling core business beyond Jakafi toward 2029 patent transitionIncyte is executing a strategic portfolio pivot to scale its non-Jakafi core business to $3B-$4B by 2030 to mitigate the upcoming 2029 Jakafi loss of exclusivity. Core business ex-Jakafi delivered $490M in Q3, up 30% YoY, driven by growth in OPZELURA, NIKTIMVO, ZYNYZ, and MONJUVI. Vendors providing clinical development, regulatory affairs, and commercialization services have substantial... | |
| Managing CMS pricing dynamics and Medicaid line extension settlementsIncyte reported net sales growth headwinds driven by expected pricing dynamics, specifically the impact of the CMS GENEROUS Model on Jakafi. Conversely, OPZELURA saw net sales driven by favorable U.S. pricing from a Medicaid line extension agreement with CMS, yielding a pro forma net sales increase of 21% versus unadjusted 36%. Healthcare regulatory compliance, pricing advisory, and... | |
| Collaborating with Tempus for real-world colorectal cancer data analysisIncyte partnered with Tempus to conduct real-world evidence analytics evaluating KRAS-mutant patient outcomes on LONSURF plus bevacizumab to benchmark control expectations for its Phase III DAWN-302 colorectal cancer trial. Life sciences data vendors and analytics platforms can target Incyte's clinical development teams for complementary synthetic control and real-world genomic analytics. The... | |
| Evaluating daraxonrasib post-progression crossover risks in clinical studyIncyte is monitoring post-progression use of competitor therapy daraxonrasib across clinical trial sites for its KRAS G12D inhibitor 734 study. To prevent differential post-progression PFS confounding between treatment arms, management has modeled contingencies to shift enrollment to international countries where daraxonrasib is not commercially approved. CROs and clinical site management... |
Signal API · MCP
Track Incyte with the Signal API
One POST /v1/companies/enrich call with incyte.com returns Incyte 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"incyte.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
10-Q at related companies
Questions about Incyte 10-Q
When did Incyte file its latest 10-Q?
What did Incyte disclose in its latest 10-Q?
What did Incyte say on its recent earnings calls?
Where can I read Incyte's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .